Design Therapeutics (DSGN) Revenue (2020)

Design Therapeutics (DSGN) reported Revenue of $33000.0 for Q4 2020, up 65.0% sequentially from $20000.0 in Q3 2020.

Design Therapeutics (DSGN) Revenue (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of Revenue data on file, last reported at $33000.0 in Q4 2020.

  • For the quarter ending Q4 2020, Revenue changed N/A year-over-year to $33000.0; the trailing twelve-month figure through Dec 2020 stood at $226000.0 (changed N/A YoY), and the FY2020 full-year result was $226000.0, changed N/A from the prior year.
  • Revenue rose to $33000.0 in Q4 2020, from $20000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $142000.0 in Q1 2020 to a low of $20000.0 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Design Therapeutics 725.54 Mn 502.72 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 33,000.00
Sep 30, 2020 20,000.00
Jun 30, 2020 31,000.00
Mar 31, 2020 142,000.00